This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The global pharmaceutical industry experienced a 13% drop in company filings mentions of bigdata in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novartis with 185% year-on-year increase, according to GlobalData’s analysis of over 603 pharmaceutical company filings.
The global pharma industry experienced an 11% rise in social media posts on bigdata in Q1 2023 compared with the previous quarter, with the highest share accounted for Eli Lilly and Co, according to GlobalData’s analysis of social media posts. Buy the report here.
With machine learning and bigdata analytics, companies can now predict market trends, enhance drug development, and create hyper-personalized campaigns. Bigdata analytics plays a crucial role in identifying prescribing patterns, understanding patient behaviors, and tailoring content strategies.
Across the industry, pharmacompanies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
The oceans of health data out there can be overwhelming for pharmacompanies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Bigdata: astronomical or genomical? ,
Time is also of the essence in drug development, as competitive product-to-market lead times help pharmacompanies improve profitability. With the advancement in digital technologies, data collection from end-users enables pharmacompanies to take notice of certain trends.
Moreover, the adoption of digital tools like mobile apps and telemedicine platforms is facilitating direct communication between pharmacompanies and end-users. As patients become more digitally savvy, pharmacompanies are investing in creating seamless digital experiences that cater to their needs and preferences.
The ‘PEP Talks’ monthly e-newsletter has approaching 50 pharmacompanies as subscribers and the inaugural ‘Patient Engagement Day’ on September 01 st achieved an inspirational number of downloads of toolkits for ways to ‘Amplify the Patient Voice’ as the launch theme. Will pharma listen, and is this even their role to do so?
They had to be nurtured and cared for, despite the fact we, as pharmacompanies, have very limited direct access to patients. ” What is different is that today we share cloud-based infrastructure and tools with non-pharmacompanies, like FMCG. Even when the willingness was there, it was just technically impossible.
That could include original observations and measurements of clinical study participants, such as lab results, imaging data, and patient medical charts. It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements.
During the pandemic, numerous digital health companies flourished due to the necessity for virtual solutions, including Komodo Health. He oversees operations, including business development, sales and marketing, and people. About the author.
.” The partners stress that this novel approach, paired with the “explosion in availability and accessibility of real-world data and real-world evidence”, as Sun states, creates an opportunity to use this new technique to supplement the evidence traditionally generated from clinical trial control groups.
Understanding the Shifts in the Pharma Landscape The pharmaceutical landscape is experiencing significant shifts, primarily due to advancements in technology and the increasing digitization of healthcare. Content marketing is another powerful tool in the pharma marketer’s arsenal.
The report also suggested that BigData was thought to be the most important partner to AI, in terms of introducing technology-related changes in the pharmaceutical sector (Figure 2). In addition to collaborating with AI-technology providers, pharmacompanies are also engaging in vertical integration.
Bigdata analysis can be enormously powerful in providing insights for business strategy throughout the pharma value chain, including in the acceleration of drug discovery and development, optimization of manufacturing processes, management of supply chains and the creation of innovative sales and marketing strategies.
And when you look through who those Twitter followers are, it’s very heavily skewed towards industry, as is the website, we’ve also put some tools on our website to be able to look at who the visitors are, by company. Don Langsdorf (EHS): 141 different pharmacompanies from around the world. John Mack (PG): Yeah.
According to a recent GlobalData report, healthcare professionals have – for the second year in a row – ranked artificial intelligence (AI) and BigData as the top two technologies revolutionising the pharmaceutical sector. The legacy of this disruption has been a rethink in the way pharmacompanies do business.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content